 | • レポートコード：MRC2-11QY03880 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は重症筋無力症治療薬のグローバル市場について調査・分析したレポートです。種類別（アセチルコリンエステラーゼ阻害剤、免疫抑制剤、ステロイド、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別重症筋無力症治療薬の競争状況、市場シェア ・世界の重症筋無力症治療薬市場：種類別市場規模 2015年-2020年（アセチルコリンエステラーゼ阻害剤、免疫抑制剤、ステロイド、その他） ・世界の重症筋無力症治療薬市場：種類別市場規模予測 2021年-2026年（アセチルコリンエステラーゼ阻害剤、免疫抑制剤、ステロイド、その他） ・世界の重症筋無力症治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の重症筋無力症治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の重症筋無力症治療薬市場分析：米国、カナダ ・ヨーロッパの重症筋無力症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの重症筋無力症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の重症筋無力症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの重症筋無力症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：GlaxoSmithKline、Novartis、Teva Pharmaceutical、Roche、Bristol-Myers Squibb、Apotex、Cipla、Biogen、AbbVie、Bausch Health、Sun Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.
The Americas accounted for the largest market share of the global myasthenia gravis disease market owing to the growing number of drug manufacturers, increasing awareness about the long-term effects of muscle dystrophy, and rising government funding for the treatment of this disease in the region. Moreover, the U.S. contributes to a significant market share in the global pharmaceutical industry.
Market Analysis and Insights: Global Myasthenia Gravis Disease Drugs Market
The global Myasthenia Gravis Disease Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Myasthenia Gravis Disease Drugs Scope and Market Size
Myasthenia Gravis Disease Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myasthenia Gravis Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
GlaxoSmithKline
Novartis
Teva Pharmaceutical
Roche
Bristol-Myers Squibb
Apotex
Cipla
Biogen
AbbVie
Bausch Health
Sun Pharmaceuticals
Market segment by Type, the product can be split into
Acetylcholinesterase Inhibitors
Immunosuppressant Drugs
Steroid
Others
Market segment by Application, split into
Hospitals
Clinics
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Myasthenia Gravis Disease Drugs Revenue
1.4 Market by Type
1.4.1 Global Myasthenia Gravis Disease Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Acetylcholinesterase Inhibitors
1.4.3 Immunosuppressant Drugs
1.4.4 Steroid
1.4.5 Others
1.5 Market by Application
1.5.1 Global Myasthenia Gravis Disease Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Myasthenia Gravis Disease Drugs Market Perspective (2015-2026)
2.2 Global Myasthenia Gravis Disease Drugs Growth Trends by Regions
2.2.1 Myasthenia Gravis Disease Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Myasthenia Gravis Disease Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Myasthenia Gravis Disease Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Myasthenia Gravis Disease Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Myasthenia Gravis Disease Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis Disease Drugs Players by Market Size
3.1.1 Global Top Myasthenia Gravis Disease Drugs Players by Revenue (2015-2020)
3.1.2 Global Myasthenia Gravis Disease Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Myasthenia Gravis Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Myasthenia Gravis Disease Drugs Market Concentration Ratio
3.2.1 Global Myasthenia Gravis Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Disease Drugs Revenue in 2019
3.3 Myasthenia Gravis Disease Drugs Key Players Head office and Area Served
3.4 Key Players Myasthenia Gravis Disease Drugs Product Solution and Service
3.5 Date of Enter into Myasthenia Gravis Disease Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Myasthenia Gravis Disease Drugs Historic Market Size by Type (2015-2020)
4.2 Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020)
5.2 Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Myasthenia Gravis Disease Drugs Market Size (2015-2020)
6.2 Myasthenia Gravis Disease Drugs Key Players in North America (2019-2020)
6.3 North America Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020)
6.4 North America Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Myasthenia Gravis Disease Drugs Market Size (2015-2020)
7.2 Myasthenia Gravis Disease Drugs Key Players in Europe (2019-2020)
7.3 Europe Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020)
7.4 Europe Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020)
8 China
8.1 China Myasthenia Gravis Disease Drugs Market Size (2015-2020)
8.2 Myasthenia Gravis Disease Drugs Key Players in China (2019-2020)
8.3 China Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020)
8.4 China Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Myasthenia Gravis Disease Drugs Market Size (2015-2020)
9.2 Myasthenia Gravis Disease Drugs Key Players in Japan (2019-2020)
9.3 Japan Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020)
9.4 Japan Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Myasthenia Gravis Disease Drugs Market Size (2015-2020)
10.2 Myasthenia Gravis Disease Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020)
11 India
11.1 India Myasthenia Gravis Disease Drugs Market Size (2015-2020)
11.2 Myasthenia Gravis Disease Drugs Key Players in India (2019-2020)
11.3 India Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020)
11.4 India Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Myasthenia Gravis Disease Drugs Market Size (2015-2020)
12.2 Myasthenia Gravis Disease Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020)
12.4 Central & South America Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Details
13.1.2 GlaxoSmithKline Business Overview
13.1.3 GlaxoSmithKline Myasthenia Gravis Disease Drugs Introduction
13.1.4 GlaxoSmithKline Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020))
13.1.5 GlaxoSmithKline Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Myasthenia Gravis Disease Drugs Introduction
13.2.4 Novartis Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Teva Pharmaceutical
13.3.1 Teva Pharmaceutical Company Details
13.3.2 Teva Pharmaceutical Business Overview
13.3.3 Teva Pharmaceutical Myasthenia Gravis Disease Drugs Introduction
13.3.4 Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020)
13.3.5 Teva Pharmaceutical Recent Development
13.4 Roche
13.4.1 Roche Company Details
13.4.2 Roche Business Overview
13.4.3 Roche Myasthenia Gravis Disease Drugs Introduction
13.4.4 Roche Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020)
13.4.5 Roche Recent Development
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Details
13.5.2 Bristol-Myers Squibb Business Overview
13.5.3 Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Introduction
13.5.4 Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020)
13.5.5 Bristol-Myers Squibb Recent Development
13.6 Apotex
13.6.1 Apotex Company Details
13.6.2 Apotex Business Overview
13.6.3 Apotex Myasthenia Gravis Disease Drugs Introduction
13.6.4 Apotex Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020)
13.6.5 Apotex Recent Development
13.7 Cipla
13.7.1 Cipla Company Details
13.7.2 Cipla Business Overview
13.7.3 Cipla Myasthenia Gravis Disease Drugs Introduction
13.7.4 Cipla Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020)
13.7.5 Cipla Recent Development
13.8 Biogen
13.8.1 Biogen Company Details
13.8.2 Biogen Business Overview
13.8.3 Biogen Myasthenia Gravis Disease Drugs Introduction
13.8.4 Biogen Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020)
13.8.5 Biogen Recent Development
13.9 AbbVie
13.9.1 AbbVie Company Details
13.9.2 AbbVie Business Overview
13.9.3 AbbVie Myasthenia Gravis Disease Drugs Introduction
13.9.4 AbbVie Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020)
13.9.5 AbbVie Recent Development
13.10 Bausch Health
13.10.1 Bausch Health Company Details
13.10.2 Bausch Health Business Overview
13.10.3 Bausch Health Myasthenia Gravis Disease Drugs Introduction
13.10.4 Bausch Health Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020)
13.10.5 Bausch Health Recent Development
13.11 Sun Pharmaceuticals
10.11.1 Sun Pharmaceuticals Company Details
10.11.2 Sun Pharmaceuticals Business Overview
10.11.3 Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Introduction
10.11.4 Sun Pharmaceuticals Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020)
10.11.5 Sun Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Myasthenia Gravis Disease Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Myasthenia Gravis Disease Drugs Revenue
Table 3. Ranking of Global Top Myasthenia Gravis Disease Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Myasthenia Gravis Disease Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Acetylcholinesterase Inhibitors
Table 6. Key Players of Immunosuppressant Drugs
Table 7. Key Players of Steroid
Table 8. Key Players of Others
Table 9. Global Myasthenia Gravis Disease Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Myasthenia Gravis Disease Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Myasthenia Gravis Disease Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Myasthenia Gravis Disease Drugs Market Share by Regions (2015-2020)
Table 13. Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Myasthenia Gravis Disease Drugs Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Myasthenia Gravis Disease Drugs Market Growth Strategy
Table 19. Main Points Interviewed from Key Myasthenia Gravis Disease Drugs Players
Table 20. Global Myasthenia Gravis Disease Drugs Revenue by Players (2015-2020) (Million US$)
Table 21. Global Myasthenia Gravis Disease Drugs Market Share by Players (2015-2020)
Table 22. Global Top Myasthenia Gravis Disease Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease Drugs as of 2019)
Table 23. Global Myasthenia Gravis Disease Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Myasthenia Gravis Disease Drugs Product Solution and Service
Table 26. Date of Enter into Myasthenia Gravis Disease Drugs Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 29. Global Myasthenia Gravis Disease Drugs Market Size Share by Type (2015-2020)
Table 30. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Type (2021-2026)
Table 31. Global Myasthenia Gravis Disease Drugs Market Size Share by Application (2015-2020)
Table 32. Global Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 33. Global Myasthenia Gravis Disease Drugs Market Size Share by Application (2021-2026)
Table 34. North America Key Players Myasthenia Gravis Disease Drugs Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Myasthenia Gravis Disease Drugs Market Share (2019-2020)
Table 36. North America Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 37. North America Myasthenia Gravis Disease Drugs Market Share by Type (2015-2020)
Table 38. North America Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 39. North America Myasthenia Gravis Disease Drugs Market Share by Application (2015-2020)
Table 40. Europe Key Players Myasthenia Gravis Disease Drugs Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Myasthenia Gravis Disease Drugs Market Share (2019-2020)
Table 42. Europe Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Myasthenia Gravis Disease Drugs Market Share by Type (2015-2020)
Table 44. Europe Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Myasthenia Gravis Disease Drugs Market Share by Application (2015-2020)
Table 46. China Key Players Myasthenia Gravis Disease Drugs Revenue (2019-2020) (Million US$)
Table 47. China Key Players Myasthenia Gravis Disease Drugs Market Share (2019-2020)
Table 48. China Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 49. China Myasthenia Gravis Disease Drugs Market Share by Type (2015-2020)
Table 50. China Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 51. China Myasthenia Gravis Disease Drugs Market Share by Application (2015-2020)
Table 52. Japan Key Players Myasthenia Gravis Disease Drugs Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Myasthenia Gravis Disease Drugs Market Share (2019-2020)
Table 54. Japan Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Myasthenia Gravis Disease Drugs Market Share by Type (2015-2020)
Table 56. Japan Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Myasthenia Gravis Disease Drugs Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Myasthenia Gravis Disease Drugs Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Myasthenia Gravis Disease Drugs Market Share (2019-2020)
Table 60. Southeast Asia Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Myasthenia Gravis Disease Drugs Market Share by Type (2015-2020)
Table 62. Southeast Asia Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Myasthenia Gravis Disease Drugs Market Share by Application (2015-2020)
Table 64. India Key Players Myasthenia Gravis Disease Drugs Revenue (2019-2020) (Million US$)
Table 65. India Key Players Myasthenia Gravis Disease Drugs Market Share (2019-2020)
Table 66. India Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 67. India Myasthenia Gravis Disease Drugs Market Share by Type (2015-2020)
Table 68. India Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 69. India Myasthenia Gravis Disease Drugs Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Myasthenia Gravis Disease Drugs Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Myasthenia Gravis Disease Drugs Market Share (2019-2020)
Table 72. Central & South America Myasthenia Gravis Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Myasthenia Gravis Disease Drugs Market Share by Type (2015-2020)
Table 74. Central & South America Myasthenia Gravis Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Myasthenia Gravis Disease Drugs Market Share by Application (2015-2020)
Table 76. GlaxoSmithKline Company Details
Table 77. GlaxoSmithKline Business Overview
Table 78. GlaxoSmithKline Product
Table 79. GlaxoSmithKline Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 80. GlaxoSmithKline Recent Development
Table 81. Novartis Company Details
Table 82. Novartis Business Overview
Table 83. Novartis Product
Table 84. Novartis Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 85. Novartis Recent Development
Table 86. Teva Pharmaceutical Company Details
Table 87. Teva Pharmaceutical Business Overview
Table 88. Teva Pharmaceutical Product
Table 89. Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 90. Teva Pharmaceutical Recent Development
Table 91. Roche Company Details
Table 92. Roche Business Overview
Table 93. Roche Product
Table 94. Roche Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 95. Roche Recent Development
Table 96. Bristol-Myers Squibb Company Details
Table 97. Bristol-Myers Squibb Business Overview
Table 98. Bristol-Myers Squibb Product
Table 99. Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 100. Bristol-Myers Squibb Recent Development
Table 101. Apotex Company Details
Table 102. Apotex Business Overview
Table 103. Apotex Product
Table 104. Apotex Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 105. Apotex Recent Development
Table 106. Cipla Company Details
Table 107. Cipla Business Overview
Table 108. Cipla Product
Table 109. Cipla Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 110. Cipla Recent Development
Table 111. Biogen Business Overview
Table 112. Biogen Product
Table 113. Biogen Company Details
Table 114. Biogen Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 115. Biogen Recent Development
Table 116. AbbVie Company Details
Table 117. AbbVie Business Overview
Table 118. AbbVie Product
Table 119. AbbVie Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 120. AbbVie Recent Development
Table 121. Bausch Health Company Details
Table 122. Bausch Health Business Overview
Table 123. Bausch Health Product
Table 124. Bausch Health Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 125. Bausch Health Recent Development
Table 126. Sun Pharmaceuticals Company Details
Table 127. Sun Pharmaceuticals Business Overview
Table 128. Sun Pharmaceuticals Product
Table 129. Sun Pharmaceuticals Revenue in Myasthenia Gravis Disease Drugs Business (2015-2020) (Million US$)
Table 130. Sun Pharmaceuticals Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myasthenia Gravis Disease Drugs Market Share by Type: 2020 VS 2026
Figure 2. Acetylcholinesterase Inhibitors Features
Figure 3. Immunosuppressant Drugs Features
Figure 4. Steroid Features
Figure 5. Others Features
Figure 6. Global Myasthenia Gravis Disease Drugs Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Myasthenia Gravis Disease Drugs Report Years Considered
Figure 11. Global Myasthenia Gravis Disease Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Myasthenia Gravis Disease Drugs Market Share by Regions: 2020 VS 2026
Figure 13. Global Myasthenia Gravis Disease Drugs Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Myasthenia Gravis Disease Drugs Market Share by Players in 2019
Figure 16. Global Top Myasthenia Gravis Disease Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease Drugs as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Myasthenia Gravis Disease Drugs Revenue in 2019
Figure 18. North America Myasthenia Gravis Disease Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Myasthenia Gravis Disease Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Myasthenia Gravis Disease Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Myasthenia Gravis Disease Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Myasthenia Gravis Disease Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Myasthenia Gravis Disease Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Myasthenia Gravis Disease Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
重症筋無力症の世界市場（～2026年） Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be …- 重症筋無力症治療の世界市場（～2026年） Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and …
- クラッベ病治療薬の世界市場（～2026年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…
- 末梢動脈疾患（PAD）薬の世界市場（～2026年） Market Analysis and Insights: Global Peripheral Arterial Disease (PAD) Drugs Market The global Peripheral Arterial Disease (PAD) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Peripheral Arterial Disease (PAD) D…
- メニエール病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Meniere Disease Drugs Market The global Meniere Disease Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Meniere Disease Drugs Scope and Market Size Meniere Disease Drugs marke…